Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2018

View Archived Issues

FN-1501 identified as a novel FLT-3 and CDK inhibitor for the treatment of AML

NIAID initiates phase I study of HIV-1 vaccines

GSK initiates phase II study of SARM GSK-2881078 in patients with COPD

Shanghai Pharmaceuticals initiates phase Ia trial with B-001 in patients with NHL

Insmed submits NDA for ALIS for nontuberculous mycobacterial lung disease

FDA grants orphan drug designation to Scholar Rock's SRK-015 for SMA

Catalyst submits NDA for Firdapse for LEMS

Pharmacokinetics of anti-HIV agent GS-9131 explored in phase I study

European Commission approves expanded indication for Xgeva

EMA accepts cemiplimab MAA for cutaneous squamous cell carcinoma

Symic reports 12-month data from SHIELD trial of SB-030 in peripheral vascular disease

EMA accepts Dupixent submission in asthma

First phase I data presented for ACT-709478 in healthy volunteers

ETC-206, a new agent for hematological cancers

FDA grants accelerated approval to Blincyto for B-cell precursor ALL with minimal residual disease

Numerate patents novel FFAR4 agonists

Roche and Genentech divulge new JAK1 inhibitors

Calithera Biosciences identifies new CD73 inhibitors

FDA approves Leukine for H-ARS

Chinese researchers discover CDK4/6 inhibitors

Novartis targets kinetoplastid proteasome for Chagas disease, leishmaniasis

Sunovion submits NDA for APL-130277 to treat off episodes associated with Parkinson's disease

Albert Einstein College of Medicine patents MSC-derived microvesicles

Motif Bio initiates rolling NDA for iclaprim

Compugen and MedImmune sign cancer immunotherapy license agreement

FDA issues refusal to file letter for Alkermes' ALKS-5461 NDA

Taiwan Liposome submits IND for TLC-590